Hutchison Chi-Med plans to file two New Drug applications for innovative cancer drugs in 2016, said Christian Hogg, CEO of the company, in an upbeat year-end earnings report. The company expects results from a Phase II trial of fruquintinib as a treatment for colorectal cancer soon, which will trigger a milestone payment from Lilly. It also expects milestones from savolitinib, a treatment for kidney and gastric cancer that is out-licensed to AstraZeneca later in 2015. Chi-Med will file for China approval of fruquintinib and US approval of savolitinib.
Help employers find you! Check out all the jobs and post your resume.
